Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-00592379 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PF-00592379 | DRUG | - |
| Sildenafil 100mg | DRUG | - |
Inclusion Criteria: * Erectile dysfunction, previous good response to an oral treatment for erectile dysfunction. Exclusion Criteria: * Patients with high blood pressure or certain heart conditions (e.g. angina, heart failure), regardless of whether treated or not. * Patients on nitrates or alpha...
PF-00592379 is an investigational small molecule being developed for the treatment of impotence, also known as erectile dysfunction. It is in Phase 2 clinical development and is being studied in male patients aged 18 years and older.
PF-00592379 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 2 clinical development for the treatment of impotence.
PF-00592379 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its efficacy and safety for the treatment of impotence.
PF-00592379 has been studied in one completed clinical trial, identified as NCT00273416. This was a randomized, double-blind, placebo-controlled, balanced 4-way crossover study that assessed the efficacy of single oral doses of the drug in 32 male participants with impotence.
No alternative names for PF-00592379 have been reported. The drug is identified solely by its development code PF-00592379 and is being investigated by Pfizer for the treatment of impotence.